Exposure–Response Analysis of Osimertinib in Patients with Advanced Non-Small-Cell Lung Cancer

High interindividual variability (IIV) of the clinical response to epidermal growth factor receptor (EGFR) inhibitors such as osimertinib in non-small-cell lung cancer (NSCLC) might be related to the IIV in plasma exposure. The aim of this study was to evaluate the exposure–response relationship for...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Thomas Rodier, Alicja Puszkiel, Evelina Cardoso, David Balakirouchenane, Céline Narjoz, Jennifer Arrondeau, Vincent Fallet, Nihel Khoudour, Monia Guidi, Michel Vidal, Xavier Declèves, Chantal Csajka, Jérôme Alexandre, Jacques Cadranel, Elizabeth Fabre, Marie Wislez, François Goldwasser, Benoit Blanchet
Format:	Artigo
Jezik:	Inglês
Izdano:	MDPI AG 2022-09-01
Serija:	Pharmaceutics
Teme:	osimertinib non-small-cell lung cancer pharmacokinetics pharmacodynamics
Online dostop:	https://www.mdpi.com/1999-4923/14/9/1844
Oznake:	Označite Brez oznak, prvi označite!